Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
Sponsor: Yong Wha Moon
Summary
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.
Official title: A Clinical Trial to Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
Key Details
Gender
FEMALE
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2025-04-01
Completion Date
2027-06-30
Last Updated
2026-06-16
Healthy Volunteers
No
Conditions
Interventions
autologous tumor-infiltrating lymphocytes
Autologous tumor-infiltrating lymphocytes are cultured from tumor cells collected from the subject and administered as a single intravenous injection to the subject.
Locations (1)
Bundang CHA Medical Center
Gyeonggi-do, Bundang-gu, South Korea